CA2399516A1 - Sulfate of quinolonecarboxylic acid derivatives and the use thereof - Google Patents
Sulfate of quinolonecarboxylic acid derivatives and the use thereof Download PDFInfo
- Publication number
- CA2399516A1 CA2399516A1 CA002399516A CA2399516A CA2399516A1 CA 2399516 A1 CA2399516 A1 CA 2399516A1 CA 002399516 A CA002399516 A CA 002399516A CA 2399516 A CA2399516 A CA 2399516A CA 2399516 A1 CA2399516 A1 CA 2399516A1
- Authority
- CA
- Canada
- Prior art keywords
- sulfate
- gatifloxacin
- cyclopropyl
- dihydro
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
The invention provides a novel sulfate salt and a hydrate thereof, which are useful in efficient recovery of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6- fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid. Specifically, the invention provides a sulfate salt of 1-cyclopropyl-7-(3-methyl-1- piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid and a hydrate of the salt, and industrial use of both.
Description
SPECIFICATION
[Title of the invention]
Sulfate of quinolonecarboxylic acid derivatives and the use thereof [Technical field]
The present invention relates to sulfate of 1-cyclopropyl -7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (International Nonproprietary Name: gatifloxacin), its use for recovering gatifloxacin and recovering method. Gatifloxacin is characterized by its chemical structure having an alkoxy group at 8-position, and is useful as an antimicrobial agent.
[Background technologies]
As a method of treating industrial waste liquor containing quinolonecarboxylic acid derivatives, it is common to recover by adsorbing effective ingredients ontosynthetic adsorbent etc., or to dispose by directly incinerating waste liquor itself without performing such recovering procedure of the like.
The method of recovering effective ingredients from industrial waste liquor containing quinolonecarboxylic acid derivatives by using synthetic adsorbent etc. is complicated procedurally and not a good method, resulting also in a cause of steep rise in preparation cost. Also, the incinerating disposal of industrial waste liquor containing a large quantity of effective ingredients cannot be said to be a preferable method from the environmental preservation.
Hence, upon preparation of gatifloxacin, it is very useful in the industry to find out a method of advantageously recovering gatifloxacin industrially from waste liquor after preparation and regenerating it.
[Disclosure of the invention]
As a result of diligent investigation on a method of industrially recovering gatifloxacin useful as an antimicrobial agent under such situation, the inventors have found that, if forming sulfate of gatifloxacin in the waste liquor etc., allowing to sediment and separate, and then freeing from salt, gatifloxacin can be advantageously recovered industrially, leading to the completion of the invention.
The inventive gatifloxacin sulfate and its hydrate are novel compounds not described in the literature. The concrete preparing method lies in that aqueous sulfuric acid is added to acidity water or water-containing alcohol dissolved or suspended gatifloxacin, thereby sedimenting sulfate of gatifloxacin. If recrystallizing this further from, for example, water, hydrate of sulfate of gatifloxacin can be obtained.
[Title of the invention]
Sulfate of quinolonecarboxylic acid derivatives and the use thereof [Technical field]
The present invention relates to sulfate of 1-cyclopropyl -7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (International Nonproprietary Name: gatifloxacin), its use for recovering gatifloxacin and recovering method. Gatifloxacin is characterized by its chemical structure having an alkoxy group at 8-position, and is useful as an antimicrobial agent.
[Background technologies]
As a method of treating industrial waste liquor containing quinolonecarboxylic acid derivatives, it is common to recover by adsorbing effective ingredients ontosynthetic adsorbent etc., or to dispose by directly incinerating waste liquor itself without performing such recovering procedure of the like.
The method of recovering effective ingredients from industrial waste liquor containing quinolonecarboxylic acid derivatives by using synthetic adsorbent etc. is complicated procedurally and not a good method, resulting also in a cause of steep rise in preparation cost. Also, the incinerating disposal of industrial waste liquor containing a large quantity of effective ingredients cannot be said to be a preferable method from the environmental preservation.
Hence, upon preparation of gatifloxacin, it is very useful in the industry to find out a method of advantageously recovering gatifloxacin industrially from waste liquor after preparation and regenerating it.
[Disclosure of the invention]
As a result of diligent investigation on a method of industrially recovering gatifloxacin useful as an antimicrobial agent under such situation, the inventors have found that, if forming sulfate of gatifloxacin in the waste liquor etc., allowing to sediment and separate, and then freeing from salt, gatifloxacin can be advantageously recovered industrially, leading to the completion of the invention.
The inventive gatifloxacin sulfate and its hydrate are novel compounds not described in the literature. The concrete preparing method lies in that aqueous sulfuric acid is added to acidity water or water-containing alcohol dissolved or suspended gatifloxacin, thereby sedimenting sulfate of gatifloxacin. If recrystallizing this further from, for example, water, hydrate of sulfate of gatifloxacin can be obtained.
Also, when recovering gatifloxacin from industrial waste liquor after preparation, aqueous sulfuric acid is added to acidity water-containing alcoholic solution dissolved gatifloxacin, thereby obtaining sulfate as sedimented crystals. These are collected by filtration and washed or recrystallized, and then dissolved or suspended into water.
Following this, if the solution is made weak alkaline with aqueous solution of alkali such as sodium hydroxide, good-quality gatifloxacin is freed, thus enabling to recover.
In addition, the recycling use is possible by adding sulfate to new preparing process without separating gatifloxacin, leaving as it is in alkaline solution.
[Best embodiment to put the invention into practice]
Moreover, the alcoholic organic solvent after recovery of gatifloxacin as sulfate can be recovered as a solvent containing no basic ingredients, hence efficient recycling use is possible.
[Example]
In following, the invention will be illustrated in detail by describing examples and referential example, but it is not confined thereto.
Example 1 Manufacture of p~e_pa_rat,'_ve sample of sulfatel Into 200mL of water were suspended 20g of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro -4-oxo-3-quinolinecarboxylic acid, which was dissolved by adding 68~ acetic acid (5mL). To this solution, 35~ sulfuric acid (lOmL) was added to make acidic. Then, the sedimented crystals were collected by filtration and washed with water.
The crystals obtained were recrystallized from 400mL of water to obtain 18.48 of 1/2 sulfate~2/5 hydrate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Melting point: 212-215°C (decomp).
Elemental analysis:
C~ H$ N$
Calcd. For C1gH22FN304~1/2H2S04~2/5H20 : 52.87 5.46 9.74.
Found . 53.00 5.57 9.99.
MS (m/e):
375 [C1gH22FN3041+
344 [C1gH22FN304-OCH3~+
331 [C1gH22FN304-0021+
319 [C1gH22FN304-C3H6Nl+
275 [C1gH22FN304'C02-C3H6N1+
260 [C1gH22FN304-C02-C4H9Nl+
NMR (1H-NMR: 400MHz,DMSO-d6): b 1.01-1.15 (7H, m, (-CH2)2 of cyclopropyl group, CH3- of piperazine ring) 3.02-3.45 (7H, m, piperazine ring) 3.78 (3H, s, CH30-) 4.14-4.20 (1H, m, -CH= of cyclopropyl group) 7 .75 ( 1H, d, J=11 . 7Hz, 5-position CH of quinolone ring) 8.71 (1H, s, 2-position CH of quinolone ring) An ethanol filtrate containing 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-metboxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid caused by recrystallization in Referential example 1 was warmed to 40°C, and 35 o sulfuric acid was added dropwise to bring to pH 4 , which was stirred for 2 hours at the same temperature.
The sedimented crystals were collected by filtration to obtain 22.88 of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Into 105mL of water, 21g of this sulfate were suspended and dissolved by adding 24.50 aqueous solution of sodium hydroxide.
This solution was recycled to hydrolyzing solution of next lot as it is.
Example 3 After 3.6L of ethanol filtrate containing 29g (content was calculated from recrystallization yield) of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro -4-oxo-3-quinolinecarboxylic acid obtained by the procedure similar to Referential example 1 was warmed to 40°C, 35%
sulfuric acid was added dropwise to bring to pH 4, which was stirred for 2 hours at 40 to 45°C.
The sedimented crystals were collected by filtration to obtain 27.98 of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Into 133mL of water, 26.5g of this sulfate were suspended and dissolved by adding 24.5% aqueous solution of sodium hydroxide. To the dissolved solution, 68% acetic acid was addedto adjust to pH 8, which was stirred for 1 hour as it is and then stirred for 10 minutes of 80 to 84°C. The sedimented crystals were collected by filtration and then washed with water to obtain 6.5g of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Example 4 After 1000L of filtrate containing 3kg (content was calculated from recrystallization yield) of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro -4-oxo-3-quinolinecarboxylic acid recrystallized using 2-propanol in place of ethanol was warmed to 40°C, 35% sulfuric acid was added dropwise to bring to pH 4, which was stirred for 2 hours at the same temperature.
The sedimented crystals were collected by filtration and then washed with 45L of water in suspended state, thereby obtaining 3.03kg of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
To 2158 of (1-cyclopropyl-6,7-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylate-03,04)bis(acetate-O)-borate were added 66.1g of 2-methylpiperazine, 1138 of triethylamine and 403g of acetonitrile, and the mixture was stirred overnight at room temperature.
The solvent was distilled off and, after added 1.24L of 0.5% acetic acid, the mixture was stirred for 3 hours at 80 to 85°C. The reaction mixture was cooled and, after added 1g of activated carbon, the mixture was stirred for 0.5 hours.
The activated carbon was separated by filtration, and to the f filtrate, 24 . 5~ aqueous solution of sodium hydroxide was added to adjust to pH 8, which was then stirred overnight at 0 to 5°C .
The sedimented crystals were collected by filtration to obtain 191g of crude crystals of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
These crude crystals were recrystallized from 90~ ethanol to obtain 1608 of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
[Utilizability in the industry]
The inventive sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (gatifloxacin) and its hydrate are novel acid adducts. It has become clear that, if forming sulfate of gatifloxacin from the waste liquor after preparation, separating and purifying by usual method, and then freeing, gatifloxacin can be advantageously recovered industrially.
The gatifloxacin recovered via sulfate can be brought to recycling use as a product. Moreover, the alcoholic organic solvent after recovery of sulfate can be recovered as a solvent containing no basic ingredients, hence efficient recycling application is possible.
Following this, if the solution is made weak alkaline with aqueous solution of alkali such as sodium hydroxide, good-quality gatifloxacin is freed, thus enabling to recover.
In addition, the recycling use is possible by adding sulfate to new preparing process without separating gatifloxacin, leaving as it is in alkaline solution.
[Best embodiment to put the invention into practice]
Moreover, the alcoholic organic solvent after recovery of gatifloxacin as sulfate can be recovered as a solvent containing no basic ingredients, hence efficient recycling use is possible.
[Example]
In following, the invention will be illustrated in detail by describing examples and referential example, but it is not confined thereto.
Example 1 Manufacture of p~e_pa_rat,'_ve sample of sulfatel Into 200mL of water were suspended 20g of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro -4-oxo-3-quinolinecarboxylic acid, which was dissolved by adding 68~ acetic acid (5mL). To this solution, 35~ sulfuric acid (lOmL) was added to make acidic. Then, the sedimented crystals were collected by filtration and washed with water.
The crystals obtained were recrystallized from 400mL of water to obtain 18.48 of 1/2 sulfate~2/5 hydrate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Melting point: 212-215°C (decomp).
Elemental analysis:
C~ H$ N$
Calcd. For C1gH22FN304~1/2H2S04~2/5H20 : 52.87 5.46 9.74.
Found . 53.00 5.57 9.99.
MS (m/e):
375 [C1gH22FN3041+
344 [C1gH22FN304-OCH3~+
331 [C1gH22FN304-0021+
319 [C1gH22FN304-C3H6Nl+
275 [C1gH22FN304'C02-C3H6N1+
260 [C1gH22FN304-C02-C4H9Nl+
NMR (1H-NMR: 400MHz,DMSO-d6): b 1.01-1.15 (7H, m, (-CH2)2 of cyclopropyl group, CH3- of piperazine ring) 3.02-3.45 (7H, m, piperazine ring) 3.78 (3H, s, CH30-) 4.14-4.20 (1H, m, -CH= of cyclopropyl group) 7 .75 ( 1H, d, J=11 . 7Hz, 5-position CH of quinolone ring) 8.71 (1H, s, 2-position CH of quinolone ring) An ethanol filtrate containing 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-metboxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid caused by recrystallization in Referential example 1 was warmed to 40°C, and 35 o sulfuric acid was added dropwise to bring to pH 4 , which was stirred for 2 hours at the same temperature.
The sedimented crystals were collected by filtration to obtain 22.88 of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Into 105mL of water, 21g of this sulfate were suspended and dissolved by adding 24.50 aqueous solution of sodium hydroxide.
This solution was recycled to hydrolyzing solution of next lot as it is.
Example 3 After 3.6L of ethanol filtrate containing 29g (content was calculated from recrystallization yield) of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro -4-oxo-3-quinolinecarboxylic acid obtained by the procedure similar to Referential example 1 was warmed to 40°C, 35%
sulfuric acid was added dropwise to bring to pH 4, which was stirred for 2 hours at 40 to 45°C.
The sedimented crystals were collected by filtration to obtain 27.98 of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Into 133mL of water, 26.5g of this sulfate were suspended and dissolved by adding 24.5% aqueous solution of sodium hydroxide. To the dissolved solution, 68% acetic acid was addedto adjust to pH 8, which was stirred for 1 hour as it is and then stirred for 10 minutes of 80 to 84°C. The sedimented crystals were collected by filtration and then washed with water to obtain 6.5g of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
Example 4 After 1000L of filtrate containing 3kg (content was calculated from recrystallization yield) of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy -1,4-dihydro -4-oxo-3-quinolinecarboxylic acid recrystallized using 2-propanol in place of ethanol was warmed to 40°C, 35% sulfuric acid was added dropwise to bring to pH 4, which was stirred for 2 hours at the same temperature.
The sedimented crystals were collected by filtration and then washed with 45L of water in suspended state, thereby obtaining 3.03kg of sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
To 2158 of (1-cyclopropyl-6,7-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylate-03,04)bis(acetate-O)-borate were added 66.1g of 2-methylpiperazine, 1138 of triethylamine and 403g of acetonitrile, and the mixture was stirred overnight at room temperature.
The solvent was distilled off and, after added 1.24L of 0.5% acetic acid, the mixture was stirred for 3 hours at 80 to 85°C. The reaction mixture was cooled and, after added 1g of activated carbon, the mixture was stirred for 0.5 hours.
The activated carbon was separated by filtration, and to the f filtrate, 24 . 5~ aqueous solution of sodium hydroxide was added to adjust to pH 8, which was then stirred overnight at 0 to 5°C .
The sedimented crystals were collected by filtration to obtain 191g of crude crystals of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
These crude crystals were recrystallized from 90~ ethanol to obtain 1608 of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid.
[Utilizability in the industry]
The inventive sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (gatifloxacin) and its hydrate are novel acid adducts. It has become clear that, if forming sulfate of gatifloxacin from the waste liquor after preparation, separating and purifying by usual method, and then freeing, gatifloxacin can be advantageously recovered industrially.
The gatifloxacin recovered via sulfate can be brought to recycling use as a product. Moreover, the alcoholic organic solvent after recovery of sulfate can be recovered as a solvent containing no basic ingredients, hence efficient recycling application is possible.
Claims (3)
1. Sulfate of 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (sulfate of gatifloxacin) or hydrate of that sulfate.
2. Use of sulfate of gatifloxacin or hydrate of that sulfate on recovering 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (gatifloxacin).
3. Method of recovering gatifloxacin, characterized in that aqueous sulfuric acid is added to acidity water or water-containing alcohol dissolved or suspended 1-cyclopropyl-7-(3-methyl-1-piperazinyl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (gatifloxacin), thereby sedimenting sulfate of gatifloxacin or hydrate of that sulfate.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-23609 | 2000-02-01 | ||
JP2000023609 | 2000-02-01 | ||
PCT/JP2001/000599 WO2001057017A1 (en) | 2000-02-01 | 2001-01-30 | Sulfate salt of quinolonecarboxylic acid derivative and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2399516A1 true CA2399516A1 (en) | 2001-08-09 |
Family
ID=18549738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002399516A Abandoned CA2399516A1 (en) | 2000-02-01 | 2001-01-30 | Sulfate of quinolonecarboxylic acid derivatives and the use thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US6582609B2 (en) |
EP (1) | EP1253149B1 (en) |
AT (1) | ATE372997T1 (en) |
AU (1) | AU2001230525A1 (en) |
CA (1) | CA2399516A1 (en) |
DE (1) | DE60130429D1 (en) |
TW (1) | TWI225057B (en) |
WO (1) | WO2001057017A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7882081B2 (en) * | 2002-08-30 | 2011-02-01 | Netapp, Inc. | Optimized disk repository for the storage and retrieval of mostly sequential data |
WO2004101547A1 (en) * | 2003-05-19 | 2004-11-25 | Hetero Drugs Limited | Purification methods of gatifloxacin and a novel form of gatifloxacin |
US7459289B2 (en) | 2004-03-08 | 2008-12-02 | North Carolina State University | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH089597B2 (en) * | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 8-Alkoxyquinolonecarboxylic acid excellent in selective toxicity and its salt, and method for producing the same |
DK164287A (en) * | 1986-03-31 | 1987-10-01 | Sankyo Co | QUINOLIN-3-CARBOXYLIC ACID DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF AND THEIR USE |
JPS63198664A (en) * | 1986-03-31 | 1988-08-17 | Sankyo Co Ltd | Quinolonecarboxylic acid derivative |
JPH11209286A (en) | 1998-01-21 | 1999-08-03 | Kyorin Pharmaceut Co Ltd | Anti-helicobacter pylori agent containing gatifloxacin |
JP5138128B2 (en) | 1998-08-21 | 2013-02-06 | 千寿製薬株式会社 | Aqueous liquid |
CN1257073A (en) | 1998-12-11 | 2000-06-21 | 国家医药管理局上海医药工业研究院 | 1-cyclopropyl-6-fluorine-7-(3-methyl piperazine-1-base)-8-methoxy-1,4-dihydrogen-4-oxochinoline-3-carboxylic acid and its salt and preparation process thereof |
-
2001
- 2001-01-30 EP EP01902665A patent/EP1253149B1/en not_active Expired - Lifetime
- 2001-01-30 AT AT01902665T patent/ATE372997T1/en not_active IP Right Cessation
- 2001-01-30 WO PCT/JP2001/000599 patent/WO2001057017A1/en active IP Right Grant
- 2001-01-30 CA CA002399516A patent/CA2399516A1/en not_active Abandoned
- 2001-01-30 DE DE60130429T patent/DE60130429D1/en not_active Expired - Lifetime
- 2001-01-30 US US10/182,445 patent/US6582609B2/en not_active Expired - Fee Related
- 2001-01-30 AU AU2001230525A patent/AU2001230525A1/en not_active Abandoned
- 2001-02-01 TW TW090102019A patent/TWI225057B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1253149B1 (en) | 2007-09-12 |
TWI225057B (en) | 2004-12-11 |
AU2001230525A1 (en) | 2001-08-14 |
DE60130429D1 (en) | 2007-10-25 |
WO2001057017A1 (en) | 2001-08-09 |
EP1253149A1 (en) | 2002-10-30 |
US20030013882A1 (en) | 2003-01-16 |
EP1253149A4 (en) | 2003-04-16 |
ATE372997T1 (en) | 2007-09-15 |
US6582609B2 (en) | 2003-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107778223B (en) | Preparation method of betrixaban maleate | |
US5057615A (en) | Process for purifying tryptophan | |
JPH0130823B2 (en) | ||
KR20090037445A (en) | Process for the purification of montelukast | |
EP1253149B1 (en) | Sulfate salt of quinolonecarboxylic acid derivative and use thereof | |
EP0251308A1 (en) | 4-Quinolone-3-carboxylic-acid derivatives, process for their synthesis and pharmaceutical preparations containing them | |
CN1235607A (en) | Preparation of physostigmine carbamate derivatives from eseretholes | |
CN112574197B (en) | Chiral purification method of compound C | |
AT397385B (en) | METHOD FOR PRODUCING CHINOLINE CARBONIC ACID DERIVATIVES | |
JP3716376B2 (en) | Optical resolving agent and method for producing optically active 3-aminopyrrolidine derivative using the same | |
CN111320622A (en) | Method for synthesizing moxifloxacin hydrochloride | |
CA1044239A (en) | 6-alkoxy-7-hydroxyquinoline-3-carboxylic acids and derivatives thereof | |
CN109776498B (en) | Preparation method of cilostazol | |
US4418016A (en) | Method for recovering omega-amino-dodecanoic acid from crystallization mother liquors | |
Ewins et al. | XV.—The synthesis of some new dimethyltetra-hydroquinolines | |
Foster et al. | Some γ-Substituted Benzoquinoline Derivatives1 | |
CA2435372C (en) | Process for purifying 20(s)-camptothecine | |
WO2006022488A1 (en) | Process for purification of cilostazol | |
SU456410A3 (en) | The method of purification of 1,4-benzodiazepin-2-one derivatives | |
US3155673A (en) | Process for preparing vitamin b | |
CN118221681A (en) | Preparation method of allopurinol | |
CN117624009A (en) | Continuous synthesis method of JAK inhibitor drug heterocyclic intermediate | |
CN116199624A (en) | Synthesis method of 2,5, 6-trichloronicotinic acid | |
NAKAGUCHI et al. | Synthesis of nocardicins from penicillins | |
JPH051035A (en) | Production of quinolinone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |